ClinicalTrials.gg
Active, not recruitingNCT04368806Updated Aug 3, 2026

A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis

A Phase 2/3 interventional study of JointStem and Placebo Control in Osteoarthritis, Knee, sponsored by Nature Cell Co. Ltd.. Active, not recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Nature Cell Co. Ltd. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
180th of 691
173 · median 72
Started
2021
with 59 others
Phase 2/3
13 of 796
1 open now
Primary completion
2027-08
later than 89 of 151 live
Registered
521st of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 180th largest by enrollment of the 691 interventional ones that give a count, is one of 60 that started in 2021, is one of 13 in phase 2/3, reaches primary completion later than 89 of the 151 other live ones, and was the 521st registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This study is a double-blind, randomized, placebo controlled, multi-center, superiority study to evaluate the efficacy and safety of JointStem, autologous adipose tissue derived mesenchymal stem cells (AdMSC), in patients diagnosed as knee osteoarthritis. Following a 2-week screening period, approximately 140 subjects will be randomly assigned into one of the following two arms in a 1:1 ratio (1 JointStem : 1 Placebo). After each subject completes 48-Weeks visit (Visit 8) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.

Read the detailed description

Study Procedures:

  • Visit 1 (Week -7) - Screening
  • Visit 2 (Week -5) - Baseline and Randomization (Lipoaspiration)
  • Visit 3 (Week 0) - Treatment (Intra-articular injection)
  • Visit 4 (Week 4) - 4 weeks follow-up
  • Visit 5 (Week 12) - 12 weeks follow-up
  • Visit 6 (Week 24) - 24 weeks follow-up
  • Visit 7 (Week 36) - 36 weeks follow-up
  • Visit 8 (Week 48) - 48 weeks follow-up (End of Study)
03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

\<Inclusion Criteria>

  1. Male or female of any race, adult aged 18 years or older
  2. Subject who had osteoarthritis of knee diagnosed (according to the clinical and American College of Rheumatology Criteria)
  3. Subject who has ≥ 45 on WOMAC function score at Screening and Baseline
  4. Subject who has knee pain ≥ 70 mm for the study knee out of 100 mm on VAS (Visual Analog Scale) at Screening and Baseline
  5. Subject who has radiographic evidence of grade 3 osteoarthritis in the study knee based on the Kellgren and Lawrence radiographic criteria
  6. Subject who has a varus angle of 5 degrees or less confirmed through radiography
  7. Subjects whose knee pain persists for at least 12 weeks (about 3 months) prior to Screening and does not improve symptoms with non-operative treatment options
  8. Subject who is willing to discontinue all pain medications for osteoarthritis except rescue medication (acetaminophen \< 3.25 g per day) at least 72 hours prior to Screening and throughout the duration of study
  9. Subject who is willing and able to give written for participation in the study

\<Exclusion Criteria>

  1. Subject who has (BMI) > 35 kg/m2
  2. Subject judged by the investigator to have a history of disease(s) (i.e., uncontrolled comorbid disease, kidney diseases, liver diseases, endocrine diseases, etc., but not limited to these diseases) that may affect the patient's participation in the study.
  3. Subject who has any of following clinically significant diseases:

    • diseases
    • Paget's disease, ochronosis, acromegaly, hemochromatosis, or Wilson's disease
    • Genetic diseases (hyperkinesia, collagen gene abnormality, etc.)
    • Inflammatory joint disorders (e.g., rheumatoid inflammation)
    • Infectious joint disorders (e.g., septic arthritis)
    • Other joint disorders (e.g., gout, recurrent pseudogout, articular fracture, primary osteochondrosis, villonodular synovitis)
  4. Subject who has any history of cancer and/or currently receiving treatment for a current cancer diagnosis.
  5. Subject who is positive in pathogenic test (, viral hepatitis, or syphilis)
  6. Subject who has heart diseases (myocardial infarction, coronary artery bypass graft surgery, arrhythmia, or other serious heart diseases) or has history of heart diseases within 6 months prior to Screening
  7. Subject who has received any intra-articular therapy in any joint within 6 months prior to Screening, or surgery on the relevant knee including articular endoscopic procedures within 6 months prior to Screening
  8. Subject who has history of prolotherapy, or rich plasma injection within 6 months prior to Screening
  9. Subject who has received long-acting hyaluronic acid injection (e.g., Synvisc-One®, etc.) within 6 months prior to Screening
  10. Subject who has history of stem cell therapy
  11. Subject who has significant lab abnormalities for the following parameters (If the value is within 10% of the listed laboratory exclusion criterion value and the value is considered not to be clinically significant by the investigator, the subject can be considered for enrollment):

    • Serum and AST > 2 x
    • Serum creatinine out of normal range
    • out of normal range
    • \< 10 g/dL for female subject and hemoglobin \< 11 g/dL for male subject
    • Platelets out of normal range
  12. Subject for whom the investigator judges the lipoaspiration can cause any problem
  13. Subject who has history of local anesthetic allergy
  14. Subject who has taken anti-inflammatory drugs (prescription and non-prescription NSAIDs), symptomatic slow acting drugs (glucosamine, chondroitin sulfate, diacerhein etc.), or oral (prednisone etc.) within 14 days prior to Screening (however, those who undergo a 14-day can participate.)
  15. Subject who is an active drug/alcohol abuser
  16. Pregnant or breast-feeding women, or women or men who are not using appropriate method of (appropriate method includes hormones, bilateral tubal ligation, and barrier method with spermicide, and intra-uterine device for women and vasectomy and barrier method with spermicide for men; subjects should agree to use appropriate method)
  17. Subject who is enrolled in any other clinical trials within 3 months from screening
  18. Subject who received the COVID-19 vaccines within 1 week from Visit 2 (Lipoaspiration, baseline)
  19. Subject who the principal investigator considers inappropriate for the study due to any other reasons than those listed above
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    JointStem

    Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)

    Drug: JointStem

  • Placebo comparator
    Placebo

    Normal Saline with Autologous Serum

    Other: Placebo Control

Interventions

  • DrugJointStem

    Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)

  • OtherPlacebo Control

    Normal Saline with autologous Serum

06

What researchers measure

Primary outcomes

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC) function Score

    Change from baseline in WOMAC function score at Week 48

    Time frame: Baseline and Week 48

  2. Visual Analog Scale (VAS) score

    Change from baseline on Visual Analog Scale (VAS) score at Week 48

    Time frame: Baseline and Week 48

Secondary outcomes

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Function)

    Change from baseline in WOMAC subscale (Function) score at Week 12, 24, and 36

    Time frame: Week 12, 24 and 36

  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Pain)

    Change from baseline in WOMAC subscale (Pain) score at Week 12, 24, 36, and 48

    Time frame: Week 12, 24, 36, and 48

  3. Total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score

    Change from baseline in total WOMAC score at Week 12, 24, 36, and 48

    Time frame: Week 12, 24, 36, and 48

  4. Visual Analog Scale (VAS) score

    Change from baseline in VAS score at Week 12, 24 and 36

    Time frame: Week 12, 24 and 36

  5. International Knee Documentation Committee (IKDC) score

    Change from baseline in IKDC score at Week 12, 24, 36, and 48

    Time frame: Week 12, 24, 36, and 48

  6. 36-Item Short Form health survey questionnaires (SF-36) score

    Change from baseline in SF-36 score at Week 12, 24, 36, and 48

    Time frame: Week12, 24, 36, and 48

  7. Kellgren-Lawrence grade

    Change from screening in Kellgren-Lawrence grade of knee osteoarthritis determined by X-ray at Week 48

    Time frame: Week 48

  8. Number and amount of rescue medication use

    The number and amount of rescue medication use at Week 12, 24, 36, and 48

    Time frame: Week 12, 24, 36, and 48

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Aug 2027, 74 months after the start.

Of 18 phase 2/3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2020
First posted
Apr 30, 2020
StartActual
May 26, 2021
Primary completionEst.
Aug 6, 2027
CompletionEst.
Aug 7, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04368806
Lead sponsor
Nature Cell Co. Ltd.
Responsible party
Sponsor
First posted
Apr 30, 2020
Start date
May 26, 2021
Primary completion
Aug 6, 2027 (estimated)
Completion
Aug 7, 2027 (estimated)
Last update
Aug 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion